Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 11/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19569429 | 0.89 | ATF4 (0.82) | ATF4 | |
| SCHEMBL20974142 | 0.87 | ATF4 (1.00) | ATF4ALDH1A1SENP2NPC1RAB9A | |
| SCHEMBL19577394 | 0.87 | ATF4 (0.57) | ATF4ALDH1A1MCL1POLBSENP2 | |
| SCHEMBL19569416 | 0.86 | ATF4 (0.86) | ATF4ALDH1A1POLBNPC1RAB9A | |
| SCHEMBL19569675 | 0.85 | ATF4 (0.76) | ATF4 | |
| SCHEMBL30026091 | 0.85 | ATF4 (0.76) | ATF4 | |
| SCHEMBL19556192 | 0.84 | ATF4 (0.89) | ATF4ALDH1A1NPC1RAB9ATSHR | |
| SCHEMBL19569418 | 0.84 | ATF4 (0.74) | ATF4ALDH1A1POLBTDP1MAPT | |
| SCHEMBL30025592 | 0.84 | ATF4 (0.74) | ATF4ALDH1A1POLBTDP1MAPT | |
| SCHEMBL19569390 | 0.84 | ATF4 (0.78) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| CN-109641844-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-112189008-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| EP-3704094-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-16 | — | — | US | disclosed |
| WO-2017193034-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ALDH1A1 3433/4885MCL1 2646/4885 |
| US-20190144440-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ALDH1A1 3433/4885MCL1 2646/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ALDH1A1 3433/4885MCL1 2646/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ALDH1A1 3433/4885MCL1 2646/4885 |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ALDH1A1 3433/4885MCL1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.